Answers are grounded in this paper and cite their sources.
Review explores mechanisms of hematocrit elevation in type 2 diabetes via SGLT2 inhibitors, suggesting renal and cardiovascular benefits.
his review focuses on the postulated mechanism underlying elevation of erythropoietin, hemoglobin, and hematocrit levels in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 (SGLT2) inhibitors and how this phenomenon is linked to reduced progression of chronic kidney disease, lower mortality, and a lower risk of heart failure hospitalization.
No takes yet. Share an insight, caveat, or question.
Sano et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: